Lipidomic profiling reveals lipid regulation to a novel LSD1 inhibitor treatment
LSD1 is lysine specific demethylase 1 which plays an important role in tumor metabolism. ZY0511 is a novel LSD1 inhibitor, systematic analyses of metabolic alterations during ZY0511 treatment will uncover the role of LSD1 implicated in cancer progression. We utilize untargeted tandem mass spectrometry for quantitative lipidomic profiling of HCT116 and Hela cells after ZY0511 treatment for 48 hours. We detected the changes of lipid metabolites in positive and negative ion modes respectively. The experiment was divided into two groups, the control group and the treatment group, each group contains 6 repeats. The levels of lipids and metabolites are presented in the attached excel file.